This transcript has been edited for clarity.
Lidia Schapira, MD: Hello. I'm Lidia Schapira, and I'm your host for this program, Medscape InDiscussion: Breast Cancer.
Before I introduce this episode's guest, I wanted to begin with a case study that we can return to talk about at the end. A 52-year-old, perimenopausal primary care physician consults with you after a recent biopsy showed a low-grade ductal carcinoma in situ (DCIS) that was detected after she had an abnormal screening mammogram. She has no known genetic risk or family history and is otherwise healthy. She met with a surgeon and radiation oncologist, and she comes to see you because she feels quite ambivalent about receiving treatment. She wants to know if she really must undergo local therapy now and consider endocrine therapy, or if it's safe to wait and see.
I can think of no better partner for this discussion than Dr Antonio Wolff, a professor of oncology and clinical trialist at Johns Hopkins. Dr Wolff's primary interest is in accelerating new treatments through trials designed to better understand the biology of breast cancer. But the breadth of his scholarship and publication extends to topics that address common management problems in breast cancer and delivery of care for cancer survivors.
